Some patients with Hurley Stage III disease were initially enthusiastic about their pain relief, however in almost all cases this feeling fell away after a couple of months, mainly because of the ongoing widespread disease activity.

Unable to load your delegates due to an error 2017 Jun;36(2):58-61. doi: 10.12788/j.sder.2017.020.Bettoli V, Zauli S, Borghi A, Toni G, Minghetti S, Ricci M, Virgili A.J Eur Acad Dermatol Venereol. Epub 2013 Mar 2.Dermatol Surg. 2015 Nov;73(5 Suppl 1):S55-61. Epub 2009 Jun 22.J Am Acad Dermatol.

2018 Dec 14;9:2965. doi: 10.3389/fimmu.2018.02965. Clipboard, Search History, and several other advanced features are temporarily unavailable.

The most important factor in patients' overall assessment of disease severity is pain. eCollection 2019.Front Immunol. eCollection 2019.Front Immunol.

TREATMENT OPTIONS Currently, Dr. Kirby says, dermatologists can offer both medical and surgical treatments for the nodules and abscesses associated with Stage 1 hidradenitis suppurativa. 2018 Dec 14;9:2965. doi: 10.3389/fimmu.2018.02965. Overall, it is estimated that in approximately 80% of the patients (Hurley Stages I and II) the (subjective) complaints are relieved by this treatment. Also, from our own experience, we have observed that 10% resorcinol in an oil-in-water (o/w) cream used for patients with HS causes no, or at the most minimal, desquamation. Once a peeling effect is achieved, the reduction or disappearance of pain will start in a few days instead of the average duration of 1 week, and the patients experience corresponding relief.In cases where the lesions are completely or partially settled after 4-6 weeks of treatment, topical resorcinol is also the preferred agent for maintenance therapy. Contact sensitization appears to be rare [26]. Once peeling occurs continue maintenance therapy of the lesions at unchanged concentrations (normally 15%)3. As far as can be gathered from the (mostly older) literature, resorcinol concentrations of up to 30% can be used in a safe way for acne. Hidradenitis Suppurative (HS) is a chronic, recurrent disease that presents with sore red lumps that look like “boils”. In another randomized controlled trial, the topical clindamycin was found to be as effective as systemic tetracycline (500 mg twice daily for 3 months) in the treatment of HS [33]. You put it on inflamed areas of your skin.

TREATMENT OPTIONSCurrently, Dr. Kirby says, dermatologists can offer both medical and surgical treatments for the nodules and abscesses associated with Stage 1 hidradenitis suppurativa. Unable to load your collection due to an error Topical 15% resorcinol for hidradenitis suppurativa: AN uncontrolled prospective trial with clinical and ultrasonographic follow-up. Maintenance therapy therefore could be important in HS because the disease tends to recur without an ongoing treatment regimen. Topical 15% resorcinol for hidradenitis suppurativa: An uncontrolled prospective trial with clinical and ultrasonographic follow-up.
Here the patient is ad-Table 21.2. Patients should be informed very clearly about the multifocal character of the disease, i.e., in addition to the high risk of recurrence, there is also the possibility of developing new lesions in the same region at some distance from the original ones and also in other anatomical regions. The duration of abscesses takes days to weeks and are always painful.

You see, I know exactly what you are going through right now, believe me, I understand because I have been there & experienced vertigo at it's worst!Resorcinol as a Keratolytic Agent in Hidradenitis Suppurativa
Please enable it to take advantage of the complete set of features! Therefore, we advise not exceeding a concentration of 20% resorcinol in general for HS therapy.

Resorcinol is incompatible with cetomacrogol creams [17].Therapy with topical resorcinol is started at the patient's first visit at a concentration of 10%. In answer to enquiries made to the Office of Side-effects of Drugs in the Netherlands it was stated that the Office did not know of any report in which a relationship between a birth defect and the topical application of resorcinol could be established, although this does not rule out the existence of such an effect.There are at least two classification systems for drug safety in pregnancy, i.e., the Swedish (FASS) and the US (FDA) systems.

(Genfarma, Maars-sen, The Netherlands).